The article analyses Section 3(d) of India’s Patents Act and its controversial role in pharmaceutical patents post-Novartis. It examines its origins, connection to EU SPCs, and the focus on preventing evergreening by emphasising enhanced efficacy.
Read more about Examining the Origins of Section 3(d) in India’s Patents Act and Its Connection to EU SPCs